Tel: 071 966 3311 Mobile: 087 972 8044 Email: info@karunaflame.com
        Karuna Flame Shop

Items in Your Cart

Your cart is empty
Visit The Shop

Karen Stewart and Kris Zurek R.N.M.H., ITEC, SNHS, Members of Microscopy Practitioners Association, Holistic Health Therapists

Holistic Health Centre,
Cloonloo, Boyle,
Co. Sligo.

Tel: 071 966 3311
Mobile: 087 972 8044
Email: info@karunaflame.com

              
qr code

Clinical Trials of DETA AP and RITM

The three main portable devices are:

  1.  DETA Devita AP  (standing for Anti-Parasite and used for eradicating microbes)
  2.  DETA Devita RITM  (in Russian this means ‘Rhythm’ and is used for all the organ systems and their pathologies)
  3.  DETA Devita COSMO (for cosmetic applications)

Clinical Trials:

The Russian scentists from Deta Elis have been experimenting during the last 20 years and have actually progressed to the point of having manufactured their own range of Bioresonance Treatment (BRT) portable devices. The Deta Elis company is spearheaded by their top scientist Dr Sergei Konoplov, a medical doctor, PhD physicist and electronic engineer. To date, company has conducted 117 clinical trials in different medical facilities throughout Russian Republic.

Given the language barrier between the Russian East and the English-speaking world, a lot of these research findings have not been released, except the ones listed below.

[This data has been translated into English by Dr. George Gorgiou, PhD ND DSc (AM)]

Moscow’s Central Military Hospital – using Bioresonance (BRT) Deta Devices in Medical Practice

This report was prepared on 17/11/1995 by the Consultant of the Central Military Hospital of Moscow, Dr. Betsoyk and Dr. Volkov.

Peripheral nervous system

This study included 20 patients aged 40 to 60 years with diseases of the peripheral nervous system (inflammation of the spinal nerve root), first and second stage hypertension, sleep disturbances and vasomotor rhinitis.

In some of these cases the patients had seen improvements after only one session with the Deta devices. In 80% of the cases there was considerable improvement and in 70% of the cases the blood pressure had normalized without using any other medication.

Another notable observation was the complete ameliation of pain in these patients. Insomnia was also improved considerably.

In this pilot study, it is clear that the Deta devices used alone can help many different neurological symptoms, as well as helping in cases of hypertension.

Pediatric Clinic No. 1, Borones (Russia) – effectiveness of the Deta-AP and Deta-Ritm devices on 341 Children with Various Diseases.

—————————————————————————-

Portable DETA devices can be programmed with 30 different treatment options.

 

Asthma in children

The survey was conducted from March 2003 to April 2005 under the supervision of assistant consultant, Dr. Gkolopkoba and T.B. pediatrician Dr. Nteineka.

341 patients were treated with the Deta devices, aged from 7 to 15 years.

These 341 children were divided into 5 groups, as follows:

Problems with vision (myopia, presbypoia and astigmatism) – 166 patients.

Problems with gastrointestinal system (chronic inflammation of the duodenum, colitis, bile dyskinesia) – 18 patients.

Autonomic Nervous System problems – 130 patients.

Musculoskeletal problems (scoliosis and osteochondrosis of the vertebral column) – 18 patients.

Respiratory problems (bronchial asthma, bronchitis) – 9 patients.

 

GROUPS HEALTH PROBLEMS PERCENTAGE IMPROVEMENT

Vision problems 66%

Gastrointestinal 98.7%

Autonomic Nervous System 97.6%

Musculoskeletal 46%

Respiratory 94.6%

The improvements that many of these children had were really quite remarkable, given that the only treatment they received was with the Deta-AP and the Deta-Ritm – no other medication was used.

The Use of the DETA devices on school children in the Children’s Anti-tuberculosis Health Resort of the city of Ufa, Russia

Doctor G.T. Khalikova

————————————————————————————–

Ascaris

The aim of the tests was to evaluate the efficiency and safety of DETA-AP and DETA-RITM devices in a Children’s Anti-Tuberculosis Health Resort.

One DETA-AP device and one DETA-RITM device were used during all the tests.

Patients medically diagnosed using clinical testing with the following diseases were treated with DETA-AP device:

–  Ascariasis;

–  Enterobiasis;

–  Lambliosis.

 

The “Antihelmetic” program was used once per week for a period of one month. At the same time the children also received antihelminthic herbs from the root of sweet flag and wormwood tinctures.

Before running the “antihelmetic” programs, the Deta AP “Drainage” programme was run for 17 minutes.

Depending on the type of helminth the following Deta AP programmes were used:

–  Seatworm;

–  Ascarid;

–  General parasites.

Immediately after each “antihelmetic” programme, the  “drainage therapy” programme was run to help eliminate toxins related to the parasite die-off – run-time 17 minutes.

If after running the anti-parasite programme,  there were mild gastrointestinal tract symptoms, then the Deta Ritm programme for “gastrointestinal tract regulation” was used for 40 minutes.

The DETA-RITM was used mainly with children having gastroduodenitis, biliary dyskinesia and cholecystitis.

For all these cases, the “Active Defense” programme was used for 40 minutes initially.  The child would then take a break for an hour, and then the “gastrointestinal tract regulation” programme was used for 40 minutes. The child would then take another break for an hour, then the “Deep Cleaning” programme was used for 40 minutes.

All children were required to drink plenty of water to help the flushing of toxins – 30 ml. water to each kilo of body weight.

The Deta devices were used with children up to 4 years old – most of the children wore the devices over their clothes in their breast pocket.

————————————————————————————

Clinical Trials to Determine the Treatment Efficacy of the DETA-AP Therapy Devices for the treatment of Pelvic Inflammatory Disease (acute and chronic forms)

This research was designed to determine the efficacy of the DETA-AP therapy devices with patients suffering from a clinically diagnosed Pelvic Inflammatory Disease (PIF), associated with Chlamydia, Mycoplasma, Ureaplasma, Cytomegalovirus (CMV), herpes II, and Human Papillovirus (HPV).

 

There were three treatment groups:

  1. GROUP 1 – took only antibiotic and antiviral prescribed medication for treating Chlamydia, Mycoplasma, Ureaplasma, Cytomegalovirus (CMV), herpes II, and Human Papillovirus (HPV).
  1. GROUP 2 – A combined treatment using the same medications as above, along with the Deta AP therapy device.
  1. GROUP 3 – Using only the Deta AP therapy device.

 

The 45 women taking part in these clinical trials were aged between 18-42 years (mean: 29 years) being treated on an outpatient basis in the maternity welfare centre № 10 of the Medical and Preventive Treatment Institution of “Maternity Hospital № 4” of Nizhny Novgorod State Medical Academy, Russia. The Principal Investigator was Prof. Borovkova, Head of Department, and Dr Pershin, Assistant Head.

All the woman included in the research had been clinically diagnosed with PID (both acute and chronic) and had clinical tests indicating the presence of chlamydia, mycoplasma, ureaplasma, CMV, herpes and HPV infections. The tests were conducted using enzyme multiplied immunoassay data and fragment detection of pathogen DNA by means of PCR.

The Local Ethical Committee of the State Health Care Institution of Nizhniy Novgorod District Clinical Hospital n.a. N.A. Semashko approved these clinical trials which were voluntary.

 

RESULTS:

The 45 women in the clinical group were divided into 2 groups:

GROUP 1 – those that combined prescription medication with the Deta AP bioresonance therapy devices.

GROUP 2 – those that used only the Deta AP bioresonance therapy devices

There was also a 3rd group of 55 women, aged 18 – 42 years, that received only prescribed medication.

The women using the Deta AP therapy devices ran them for an average of 40 – 60 minutes – there were three programmes ran every other day along with detoxification programmes.

There were frequent clinical examinations conducted to determine progress using clinical pelvic examination, ultrasound, thermography as well as blood analysis and microbiological assay of vaginal samples.

 

CONCLUSIONS:

  • It is interesting to note that the overall success of treatment using only prescribed medications was about 60 – 65%. This was for the treatment of the various microorganisms in question.
  • When the medications were combined with the use of the Deta AP device, the treatment outcome increased to 87 – 92%.
  • When the Deta AP device was used alone with no medications given, the treatment outcome was 85%.

The absence of any adverse side effects using the Deta AP devices resulted in the researchers concluding that bioresonance therapy was an excellent way of treating the underlying microbial caused of Pelvic Inflammatory Disease, either in the clinical setting or at home.

 

Testing the Efficacy of the DETA- Devita AP devices as part of treating patients having Pulmonary Tuberculosis (TB)

TB2 – The aim of this clinical pilot study was to determine the efficacy of the Deta AP bioresonance devices with patients that had been clinically diagnosed with Pulmonary TB, including multiple drug-resistant TB.

The trials were conducted at the State Health Care Institution of the Yaroslavl Region Regional Clinical Hospital for Tuberculosis, Russia.

Twenty five patients having tuberculosis were tested, among them there were 11 women, 14 men and 9 of these patients had multiple drug-resistant tuberculosis.

The age of the men was from 24 to 56 years old, the women from 24 to 58 years old.

The Deta AP therapy programme “Tuberculosis” was run for the prescribed period of time, once per week for 30 days. Criteria for assessing the efficiency of treatment were clinical, radiological and bacteriological examinations.

Radiological improvements were observed in 18 cases (72%); a further 6 cases (24%) had no change and only 1 case got worse (4%).

According to the bacteriological examination, a complete eradication of the TB bacterium was seen in 12 cases (48%), BK (-) in 8 cases before and after the examination, with 4 patients that were still positive.

It should be noted that all programmes of the devices are well-tolerated, and there were no adverse reactions to the treatment.

Conclusions:

  1. DETA-AP treatment is safe for TB infections.
  1. The applied treatment protocols for TB should be further developed – increasing exposure time, multiple sessions, extending the duration of treatment from one month to 2-4 months.